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Abstract
Background/Aim. The Glu298Asp variant in exon 7 and T-786C
mutation in the 5'-flanking region of the endothelial nitric oxide
synthase (eNOS) gene, paraoxonase I gene (PON1), and α2β-
adrenergic receptor gene (α2β-AR) have been reported to be genetic
risk factors for coronary heart disease (CHD). The aim of this study
was to investige the effects of these four genetic polymorphisms on
the probability of death due to CHD, using data obtained from
medico-legal autopsies. Methods. Blood samples from three groups:
healthy controls, dead cases with CHD and without CHD (the latter
as a control for dead cases) were used. After DNA extraction, geno-
typing was performed by polymerase chain reaction − restriction
fragment length polymorphism (PCR-RFLP) test. Results. The fre-
quency of the T allele in Glu298Asp variant in the dead cases with
CHD was significantly higher than that in the healthy control
(p  <  0.001, OR  =  4.47) and that in the dead cases without CHD
(p < 0.001, OR = 7.62). The gene frequency of PON1 was signifi-
cantly different (p  =  0.007) between dead cases with and without
CHD, and was also significantly different (p = 0.025) between the
healthy control and dead cases without CHD. The gene frequency of
PON1 was not significantly different (p  =  0.401) between the
healthy controls and dead cases with CHD. Hence this gene was not
associated with death due to CHD. The other polymorphisms (T-
786C mutation, α2β-AR) also showed no effect on death due to
CHD. Conclusion. The polymorphism of Glu298Asp eNOS gene
in dead cases may be useful for determining the cause of death in
CHD cases in the Japanese population.
Key words:
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disease; risk factors; polymorphism, genetic.
Apstrakt
Uvod/Cilj. Kao genetski faktori rizika za koronarna srčana
oboljenja (KSO) navedeni su varijanta Glu298Asp u egzonu 7 i
T-786C mutacija u 5'-flankirajućoj zoni endotelnog azot-oksid
sintaza (eNOS) gena, paraoksanaza 1 gena (PON1), i α2β-
adrenergički receptor gena (α2β-AR). Cilj ovog istraživanja bio je
da se ispitaju uticaji ova četiri genetska polimorfizma na moguć-
nost smrti od KSO uz korišćenje podataka dobijenih na
kliničkim autopsijama. Metode. Uzeti su uzorci krvi od tri grupe:
zdravi kontrolni, smrtni slučajevi sa i bez KSO (ovi drugi kao
kontrolni za umrle slučajeve). Posle ekstrakcije DNK izvršeno je
određivanje genotipa pomoću polymerase chain reaction − restriction
fragment lenght polymorphism (PCR-RFLP) testa. Rezultati.
Učestalost T alela u Glu298Asp varijanti kod umrlih sa KSO bila
je značajno veća nego kod zdravih kontrolnih (p < 0,001,
OR = 4,47) i umrlih slučajeva bez KSO (p < 0,001, OR = 7,62).
Genska učestalost PON1 razlikovala se značajno (p = 0,007) iz-
među smrtnih slučajeva sa i bez KSO, a razlikovala se takođe
značajno (p = 0,025) između zdravih osoba i umrlih bez KSO.
Genska učestalost PON1 nije se značajno razlikovala (p = 0,401)
između zdravih osoba i umrlih sa KSO. Ovaj gen nije se, zbog
toga, dovodio u vezu sa smrću od KSO. Drugi polimorfizmi (T-
786C mutacija, α2β-AR) takođe nisu uticali na smrt od KSO.
Zaključak. Polimorfizam Glu298Asp eNOS gena kod umrlih
može da se iskoristiti za određivanje uzroka smrti kod osoba sa
KSO u japanskoj populaciji.
Ključne reči:
medicina, sudska; smrt, iznenadna srčana; koronarna
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Introduction
Many of the causes of sudden unexpected natural death are
attributable to circulatory organ diseases. The most frequently
detected of these is ischemic heart disease, whose main cause
are coronary organic stenosis, coronary artery spasm and steno-
sis of coronary artery by thrombosis. In fatal causes of coronary
spasm, there is no evidence of pathological abnormalities of the
heart at medico-legal autopsy, and the mechanism underlying
this type of coronary spasm is unclear. The prevalence of coro-
nary spasm is higher in the Japanese population than in Cauca-
sians, suggesting that genetic factors may be related to heart dis-
ease 
1, 2. It has been reported that the Glu298Asp variant and T-
786C mutation in the endothelial nitric oxide synthase (eNOS)
gene 
3−11, the PON1 gene 
12−16 and the α2β-adrenergic receptor
gene (α2β-AR) 
17−19 are associated with cardiac heart disease
(CHD). Therefore, we examined the relationship between the
polymorphisms of these genes and fatal CHD in medico-legal
autopsy cases and postmortem examination cases.
Nitric oxide (NO), produced by the NO synthase en-
zyme, plays an important role in the regulation of blood
pressure and regional blood flow. Two polymorphisms of the
eNOS gene were found to be associated with CHD. One was
the Glu298Asp variant in exon 7 of the eNOS gene, which
has been reported to be a risk factor for acute myocardial in-
farction 
3, 4, coronary spasm 
5, coronary artery disease 
6, and
essential hypertension 
6−9 in Japanese. The other was a T to C
conversion at nucleotide position -786 in the 5'-flanking re-
gion of the eNOS gene (T-786C); this conversion was asso-
ciated with coronary spasm 
5, 7.
Furthermore, oxidative stress may contribute to the
pathogenesis of coronary spasm 
12. Lower serum PON1 activ-
ity is associated with oxidative stress 
20. PON1 is expressed as
alleles Q and R. The Q allele codes for glutamine and the R
allele for arginine at position 192 of the paraoxonase enzyme
13. Compared to the PON1-192Q allele, the PON1-129R allele
in PON1 is less able to protect high density lipoprotein by in-
hibiting the accumulation of lipid peroxidase
 21, 22. It has been
reported that the Gln192Arg (Q192R) polymorphism of PON1
was associated with the risk for coronary artery spasm 
12,
coronary heart disease, and atherosclerotic disease 
14, 15.
An insertion/deletion polymorphism in α2β-AR was also
a novel genetic risk factor for acute coronary events such as
acute myocardial infarction and sudden cardiac death 
17, 18.
Vasoconstriction has been suggested to trigger acute coronary
events, and the α2β-adrenergic receptor mediates coronary
vasoconstriction in humans 
23. It was also demonstrated that
the activation of α2β-adrenergic  receptor gene reduces coro-
nary blood flow in both normal and atherosclerotic arteries 
19.
The aim of the present study was to clarify whether any
of four polymorphisms - eNOS Glu298Asp, eNOS T-786C,
PON1, and α2β-AR - were risk factors for CHD cases in
medico-legal autopsies.
Methods
Samples
Blood samples were collected from healthy adults and
from dead cases with or without CHD by medico-legal
autopsies and postmortem examination. Healthy control
blood samples were obtained from Kagawa University stu-
dents (ranging in age from 21−27 years) who were geneti-
cally unrelated to each other. The numbers of blood samples
tested were as follows: eNOS, Glu298Asp: n = 249, eNOS,
T-786C: n = 215, PON1: n = 84, α2β-AR: n = 90.
Blood samples were also collected from medico-legal
autopsy and postmortem examination cases with or without
CHD. CHD was classified as follows: coronary atheroscle-
rotic heart disease plus chronic ischemic heart disease (17
cases), myocardial infarction (7 cases), hypertensive heart
disease (11 cases), and acute cardiac death (3 cases). Of the
dead cases without CHD, the causes of death were accidents,
suicides, murders, or diseases other than heart disease.
Extraction of genomic DNA
DNA was isolated from blood samples using a PURE-
GENE
TM DNA purification kit (Gentra Systems, USA) ac-
cording to the manufacturer's protocol.
Genotyping
The genotypes of Glu298Asp in eNOS, PON1, and α2β-
AR were determined according to the previously published
protocols 
6, 13, 17. We investigated the genotype of the T-786C
mutation in eNOS by PCR- RFLP method. The primer set and
PCR conditions were as follows: sense primer, 5'-
ATGCTCCCACCAGGGCATCA-3; antisense primer, 5'-
GTCCTTGAGTCTGACATTAGGG-3' 
10; the PCR cycling
conditions were 30 cycles at 94 °C for 1min, 59 °C for 1min
and 72 °C for 1min. The 236 bp PCR product was digested by
the Nae I, restriction enzyme (TAKARA SHUZO Co., LTD,
Japan). The restriction digest products were 236 bp in the T
allele, and 202 and 34 bp in the C allele.
The restriction digest products of the eNOS and PON1
genes were separated by electrophoresis on 4% GTG agarose
gel (NuSieve GTG: SeaKem GTG = 3:1, BMA, USA). That of
the α2β-AR gene was separated on 3.5% MethaPhor agarose
gel (BMA, USA) and visualized by using ethidium bromide.
Statistical analyses
Significant differences in the allelic frequencies among
the three study subject groups (healthy controls, autopsy
cases with CHD, and autopsy cases without CHD) were
analyzed using Fisher's exacts test. A p value of less than
0.05 was taken to be significant. Odds ratios (approximating
relative risk) were calculated as an index of the association
of each gene genotype (normal homozygote, heterozygote,
abnormal homozygote) with various heart diseases.  The ef-
fect of the mutant allele was assumed to be additive (T allele
vs. G allele for Glu298Asp, C allele vs. T allele for T-786C
mutation, R allele vs. Q allele for PON1, and D allele vs. I
allele for α2β-AR).
Results
Polymerase chain reaction − Restriction fragment
lenght polymorphism (PCR-RFLP) analyses of the
Glu298Asp variant of exon7 in the eNOS gene, PON1,  andVolumen 63, Broj 4 VOJNOSANITETSKI PREGLED Strana 359
Ameno K, et al. Vojnosanit Pregl 2006; 63(4): 357–363.
α2β-AR were reported previously. The genotyping of the
T-786C mutation of 5'-flanking region in the eNOS gene
has been performed by hybridizing using the allele specific
oligonucleotide method with 32P-radiolabeled oligonu-
cleotide T-786 probe and C-786 probe 
10. We performed a
PCR-RFLP analysis of  the T-786C mutation without RI.
The PCR products of the heterozygote (T/C) and homozy-
gote (C/C) determined by our PCR-RFLP method were se-
quenced. It was confirmed that our genotyping method was
appropriate.
Table 1 shows the genotype distributions, allele  fre-
quencies, and odds ratios of the eNOS gene missense
Glu298Asp and T-786C mutation, PON1 (Q192R), and α2β-
AR. In the Glu298Asp gene, in which the G to T conversion
at nucleotide position 894 in exon 7 of the eNOS gene results
in the replacement of glutamic acid by asparatic acid, the T
allele frequency in dead cases with CHD was significantly
higher than that in the healthy controls and that in the dead
cases without heart disease (p < 0.001, OR = 4.47). The fre-
quency of this allele differed significantly between the con-
trol group and dead cases with CHD group (p < 0.001,
OR  =  7.62) and between without and with CHD groups
(p < 0.001). There was no significant difference between the
healthy control and dead cases without CHD. These results
suggested that the Glu298Asp gene is associated with CHD.
Significant differences were found in PON1 between
dead cases with and dead cases without CHD (p = 0.007,
OR = 2.44) as shown in Table 1. The frequency of the R al-
lele in dead cases with CHD was higher than that in the dead
cases without CHD.  However, there was a significant differ-
ence between the healthy control group and dead cases with-
out CHD (p = 0.025,  OR = 1.88),  and  no  differences  were
found in the R allele frequency between the healthy control
and dead cases with CHD. This suggests that there is no as-
sociation between the mutation of PON1 and cardiac death.
Suehiro et al. 
16 also reported no association between the
PON1 gene and dead cases with CHD.
There were no significant differences among the three
groups in the allele frequencies of T-786C and α2β-AR
genes.
Table 2 shows the genotype distributions and allele fre-
quencies for the polymorphisms of eNOS Glu298Asp, eNOS
T-786C, PON1, and α2β-AR in the characterization of car-
diac death and controls. CHD was classified into 4 groups:
1) coronary atherosclerotic heart disease + chronic ischemic
heart disease (these heart diseases had similar characteristics
of cardiac death and were classified as one group), 2) myo-
cardial infarction, 3) hypertensive heart disease, and 4) acute
cardiac death. As the number of subjects in each group was
very small, statistical analysis could not be performed. How-
ever, based on the small quantity of data that we do have
from these four groups, we dare to discuss the relationships
between these four genes and allelic distributions.
Discussion
The frequency of the T allele of the Glu298Asp gene in
the myocardial infarction group was higher than in the other
grups, except for the acute cardiac death group, which had
only 2 subjects. The distribution in T/T of myocardial in-
Table 1
Genotype distributions and allele frequencies for olymorphisms of eNOS Glu298Asp, eNOS T-786C,
PON1 and α2B-AR in study subject
Control (I)
Dead cases with
CHD (II)
Dead cases without
CHD (III) Significance OR (95% CI)
eNOS, Glu298ASp (n = 249) (n = 36) (n = 23) (I) vs (II) p < 0.001 4.47 (4.0−7.6)
Genotype GG 200 (80.3%) 16 (44.4%) 21 (91,3%) (II) vs (III) p < 0.001 7.62 (2.5−23.7)
GT 45 (18.1%) 15 (41.7%) 1 (4.35%) (I) vs (III) p = 0.610 infinite
TT 4 (1.6%) 5 (13.9%) 1 (4.35%)
Allele frequency G 0.894 0.653 0.935
T 0.106 0.341 0.065
eNOS, T-786C (n = 215) (n = 37) (n = 22)
Genotype TT 181(87.9%) 33 (89.2%) 17 (77.3%) (I) vs (II) p = 1 infinite
TC 24 (11.6%) 4 (10.8%) 5 (22.7%) (II) vs (III) p = 0.291 infinite
CC 4 (1.6%) 0 (0.0%) 0 (0.0%) (I) vs (III) p = 0.206 infinite
Allele frequency T 0.907 0.946 0.886
C 0.093 0.054 0.114
PON1, Glu192Arg (n = 84) (n=37) (n = 44)
Genotype QQ 22 (26.2%) 7 (18.9%) 19 (43.2%) (I) vs (II) p = 0.401 infinite
QR 35 (41.7%) 16 (43.3%) 17 (38.6%) (II) vs (III) p = 0.007 2.44 (1.30−4.6)
RR 27 (32.1%) 14 (37.8%) 8 (18.2%) (I) vs (III) p = 0.025 1.88 (1.11−3.18)
Allele frequency Q 0.470 0.405 0.625
R 0.530 0.595 0.375
α2B-AR (n = 90) (n = 36) (n = 44)
Genotype II 36 (41.1%) 14 (38.9%) 19 (43.2%) (I) vs (II) p = 0.314 infinite
ID 41 (45.6%) 13 (36.1%) 20 (45.5%) (II) vs (III) p = 0.257 infinite
DD 12 (13.3%) 9 (25.0%) 5 (11.3%) (I) vs (III) p = 0.786 infinite
Allele frequency I 0.639 0.569 0.659
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farction in our data was 28.6%, and those of the healthy
controls and the dead cases without heart disease were 1.6%
and 4.3%, respectively. Hibi et al. 
6 reported also that the rate
of T/T (Asp/Asp) of Glu298Asp in acute myocardial infarc-
tion was 2.2%, versus 0.1% in a control group, and suggested
an association between homozygous mutation (T/T) and
acute myocardial infarction.
There have been two opposing reports on an association
between hypertensive heart disease and Glu298Asp.  Miya-
moto et al. 
9 reported that the distribution of G/T plus T/T in
hypertensive heart disease was 21.7% against 10.6% in a
control. In contrast, Tsujita et al. 
11 reported no association
between Glu298Asp and hypertension. In our experiment,
the distributions of G/T plus T/T in the dead cases with hy-
pertension, healthy control, and dead cases without CHD
were 50%, 19.7%, and 8.7%, respectively. The mutation may
affect somewhat the cause of death by these CHD.
The frequency of the C allele in eNOS T-786C in the
four disease groups of dead cases with CHD (C = 0-0.083)
was lower than that in the healthy control group (C = 0.093)
and that in the dead cases without CHD (C  =  0.114). The
C/C genotype was not found in any of the dead cases. No as-
sociation between eNOS T-786C and CHD was found in this
study. Kajiyama et al. 
8 also reported no association of T-
786C polymorphism with hypertention. There was no asso-
ciation between the healthy control and CHD in PON1, as
shown in Table 1. But the frequency of the R allele was
higher in myocardial infarction (R  =  0.714), hypertensive
heart disease (R = 0.636), and acute cardiac death (R = 0.75)
than healthy control (R  =  0.530) and dead cases without
CHD (R = 0.530).
Although the frequency in the D allele of α2β-AR did
not differ significantly among the three subject groups
(healthy control, dead cases with CHD, and dead cases with-
out CHD) as shown in Table 1, the frequency of D allele in
two of the disease classification in Table 2 - myocardial in-
farction in (D = 0.50) and coronary atherosclerotic heart dis-
ease plus chronic ischemic heart disease (D = 0.571) - was
high, suggesting an association between the D allele and
death in those two groups. Snapir et al. 
18 reported that the
DD genotype gene was a risk factor for prehospital fatal
myocardial infarction and sudden cardiac death, and that the
risk was especially high in middle-aged (under 55 years)
men from eastern Finland. The DD genotype group had a
three fold greater risk for an acute coronary event than the ID
group 
18.
The differences between the average age of the
healthy control group and those of the two groups of dead
cases were large, whereas the difference between the two
groups of dead cases was not significant. The healthy con-
trol subjects ranged from 21−27 years old, whereas the av-
erage ages of the dead cases with and without CHD was
73.8±10.8 and  63.2±15.3 years, respectively. There were
several reports on the distributions of these genes in Japa-
nese 
5, 6, 10, 14, 16, 22 and the frequency of each allele in the
control groups (age range 40−70 years) in those reports was
almost the same as in our healthy control group. So, we
used our healthy subjects as controls even though they were
younger than the dead cases. We did not study the effects
of other risk factors, such as cigarette smoking, cholesterol
value, blood pressure, or diabetes mellitus affecting NO
producing or paraoxonase activity. The body mass index
(BMI) did not differ significantly between the two groups
of dead cases: 22.8±4.12 for those with CHD and 22.9±7.5
for those without.
Recently, Polisecki et al. 
24 reported a possible associa-
tion between mtDNA 4977 bp common deletion and sudden
natural death (SND). This information may be a useful tool
for obtaining additional information to clarify investigations
into complex SND.
Table 2
Genotype distributions and allele frequencies for polymorphisms of eNOS Glu298Asp, eNOS T-786C,
PON1 and α2B-AR in the characterization of CHD and controls
Gene types
eNOS, Glu298Asp eNOS, T-786 C PON1 (Glu192Arg) α2β-AR
GG GT TT TT TC CC QQ QR RR II ID DD
Coronary atherosclerotic heart
disease + Chronic ischemic heart
disease
8 7 21 5 2 06 5 65 6 5
Allele frequencies G=0.676 T=0.324 T=0.941 C=0.058 Q=0.50 R=0.50 I=0.050 D=0.50
Myocardial infarction 3 2 2 5 1 0 0 4 3 2 2 3
Allele frequencies G=0.571 T=0.428 T=0.917 C=0.083 Q=0.286 R=0.71 I=0.429 D=0.571
Hypertensive heart disease 5 4 1 10 1 0 1 6 4 5 5 1
Allele frequencies G=0.70 T=0.30 T=0.954 C=0.054 Q=0.364 R=0.63 I=0.682 D=0.318
Acute cardiac disease 0 2 0 3 0 0 0 1 1 2 0 0
Allele frequencies G=0.50 T=0.50 T=1.0 C=0 Q=0.25 R=0.75 I=1.0 D=0
Controls withoutCHD Allele freq. G=0.935 T=0.065 T=0.886 C=0.114 Q=0.625 R=0.375 I=0.659 D=0.341
Healthy                       Allele freq. G=0.895 T=0.106 T=0.907 C=0.093 Q=0.470 R=0.530 I=0.639 D=0.361Volumen 63, Broj 4 VOJNOSANITETSKI PREGLED Strana 361
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Conclusion
The present study implies that the mutation of the
Glu298Asp gene of eNOS may be linked to deaths due to
CHD in the Japanese population. It is considered that the
Glu298Asp variant of the eNOS gene may be one of the
risk factors for cases with CHD in medico-legal autopsies.
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